APSR2026-367

Yes
Late-Breaking
Submitted
Oral Presentation
AO07-005
 
 
https://storage.unitedwebnetwork.com/files/1285/1219525-46903-APSR 2026-367 _Oral_433562.pptx
Format: PPTX Only
 
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Kuang-Ming Liao * Chi Mei Medical Center, Chiali Division of Chest Medicine/Department of Internal Medicine Tainan Taiwan
Chia-Yu Kuo - Chi Mei Medical Center Department of General Medicine Tainan Taiwan
Sheng-Chi Huang - Chi Mei Medical Center Department of General Medicine Tainan Taiwan
Wan-Hsuan Hsu - Chi Mei Medical Center Department of Internal Medicine Tainan Taiwan
Ya-Wen Tsai - Chi Mei Medical Center Division of Preventive Medicine Tainan Taiwan
Jheng-Yan Wu - Chi Mei Medical Center Department of Nutrition Tainan Taiwan
Chih-Cheng Liao - Chi Mei Medical Center Department of Intensive Care Medicine Tainan Taiwan
 
 
 
 
 
 
 
 
Presenting Author Details
Kuang-Ming
Liao
abc8870@yahoo.com.tw
+886910664560
41-50
Taiwan
Original Research
Glucagon-like peptide-1 receptor agonists and the risk of pneumonia in non-diabetic adults with obesity
Maximum 25 words
Abstract Content
Obesity increases susceptibility to pneumonia through altered lung mechanics and immune dysfunction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective obesity treatments with potential anti-inflammatory properties, but their comparative respiratory safety remains unclear.
We conducted a retrospective cohort study using the TriNetX US Collaborative network of electronic health records from 70 healthcare organizations. We identified non-diabetic adults with obesity who initiated GLP-1RAs or other weight-loss medications between January 2014 and June 2025. Using propensity score matching (PSM and an active-comparator, new-user design, we compared the risk of incident pneumonia over one year of follow-up. Secondary outcomes included aspiration pneumonia and all-cause mortality.
After PSM, 537,982 patients were included in each treatment group. The incidence of pneumonia was 9.0 events per 1000 person-years in the GLP-1RA group and 12.8 events per 1000 person-years in the control group. GLP-1RA use was associated with a lower risk of pneumonia (hazard ratio, 0.69; 95% confidence interval, 0.67 to 0.72). Risk reductions were consistent across age, sex, and body-mass index subgroups. GLP-1RA use was also associated with lower risks of aspiration pneumonia (hazard ratio, 0.39; 95% CI, 0.34 to 0.45) and all-cause mortality (hazard ratio, 0.27; 95% CI, 0.26 to 0.29).
Among adults with obesity, initiation of GLP-1RAs was associated with a significantly lower risk of pneumonia compared with other weight-loss medications, with additional benefits for aspiration pneumonia and mortality. These findings suggest important respiratory safety advantages of GLP-1RAs in obesity management.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Glucagon-like peptide-1 receptor agonists, obesity, pneumonia.
maximum 3 keywords and no abbreviations, separated by commas
 
250